Efficacy of MND-2119 in Participants With Hypertriglyceridemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 580 participants.

Also called NCT03693131

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 580 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03693131
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03693131. Randomized; quadruple masking; primary purpose treatment. Start 2018-10-27 (actual); primary completion 2019-06-15 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy of MND-2119 in Participants With Hypertriglyceridemia
Condition
Hypertriglyceridemia
Intervention (Drug)
Icosapent (MND-2119)
Intervention (Drug)
Icosapent (EPADEL CAPSULES 300)
Lead sponsor
Mochida Pharmaceutical Company, Ltd. (class: industry)

Record details

Record id
cardio:ct-nct03693131
Content hash
9dbc4af4852200ff9357a85e11cfab8118d482d6de5e00f4c80d31cc7f9c658b